CALL US TODAY
Memory Loss | Agitation / Dementia | Neuropathic Pain | Migraines|
Our Center, under the direction of Dr. Michael Tuchman, is one of South Florida’s most successful clinical research organizations. Our team studies promising medications, and we are dedicated to the highest quality clinical research. We conduct Phase II, III and IV studies, as well as outpatient Phase I trials.
We provide optimal patient care while searching for safe and effective medical solutions.
Before a new medication is available at the pharmacy for patient use, a great amount of research is required to prove that the drug is safe, effective and that it works as intended. New medications must pass a series of tests called clinical studies. The process of these studies has been carefully developed through many years of research.
Palm Beach Neurological Center conducts Phase II, Phase III and Phase IV studies. Phase II studies are tightly controlled studies which take the first look at the drug’s effectiveness. Phase III studies have expanded patient populations and are used to gain further experience with the investigational drug and determine final FDA approval. Phase IV studies are performed to compare similar drugs and to substantiate certain marketing claims with regards to the drug’s effectiveness. All of the information gathered during each phase of these studies is accumulated by the pharmaceutical company and the Federal Drug Administration for analysis and verification.
Palm Beach Neurological Center is staffed with board certified physicians, registered nurses and clinical research professionals with expertise in conducting clinical research studies to evaluate the safety and effectiveness of investigational medications. We have worked with the following major pharmaceutical companies conducting clinical research trials on medications in the process of seeking FDA approval, as well as post approval follow up studies.
|AbbottAlexzaAstraZenecaBayerBoehringer IngelheimBristol-Meyers Squibb
Forest Research Institute
|Hoeschst Marion RousselJanssenKadmusLundbeckMerckNeurochem